Update on extended treatment for venous thromboembolism

Eduardo Peñaloza-Martínez, Pablo Demelo-Rodríguez, Marco Proietti, Guillermo Soria Fernández-Llamazares, Cristina Llamazares-Mendo, Luis Álvarez-Sala Walther, Alberto M. Marra, Jorge del Toro-Cervera

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The importance of assessing the probability of venous thromboembolism recurrence, a condition that includes deep vein thrombosis and pulmonary embolism, lies in the fact that it is the most important factor in deciding the duration of anticoagulant treatment. Risk of recurrence depends mostly on the presence of a risk factor for developing venous thromboembolism, with patients with unprovoked events being at the higher risk of recurrence. The risk of recurrence needs to be balanced with the risk of bleeding and the potential severity of these thrombotic and hemorrhagic events. In patients with an unprovoked venous thromboembolism who complete treatment for the acute (first 10 days) and post-acute phase of the disease (from day 10 to 3–6 months), the decision has to be made regarding prolonged antithrombotic therapy to prevent recurrences. The main goal of extended treatment is preventing recurrences with a safety profile in terms of bleeding risk. Many therapeutic options are now available for these patients, including antiplatelet therapy with aspirin or direct oral anticoagulants. Moreover, apixaban and rivaroxaban at prophylactic doses have demonstrated efficacy in preventing recurrences with a low risk of bleeding.Key messages Extending treatment (longer than 3–6 months) is challenging in patients with venous thromboembolism (VTE) and depend on the risk of venous thromboembolism recurrence, the bleeding risk and patient and physician preferences. Anticoagulation treatment should be stopped in patients with provoked VTE and in those with unprovoked VTE and a high bleeding risk after an initial period of 3–6 months. There are some therapeutic alternatives (including Aspirin and low dose of some NOACs) to reduce venous thromboembolism recurrence risk in patients with unprovoked VTE and a low bleeding risk for extended treatment of VTE (after an initial period of 3–6 months).

Original languageEnglish
JournalAnnals of Medicine
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Venous Thromboembolism
Recurrence
Hemorrhage
Therapeutics
Anticoagulants
Aspirin
Patient Preference
Acute Disease
Pulmonary Embolism
Venous Thrombosis
Physicians
Safety

Keywords

  • Anticoagulation
  • bleeding
  • venous thromboembolism

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Peñaloza-Martínez, E., Demelo-Rodríguez, P., Proietti, M., Soria Fernández-Llamazares, G., Llamazares-Mendo, C., Álvarez-Sala Walther, L., ... del Toro-Cervera, J. (Accepted/In press). Update on extended treatment for venous thromboembolism. Annals of Medicine. https://doi.org/10.1080/07853890.2018.1538564

Update on extended treatment for venous thromboembolism. / Peñaloza-Martínez, Eduardo; Demelo-Rodríguez, Pablo; Proietti, Marco; Soria Fernández-Llamazares, Guillermo; Llamazares-Mendo, Cristina; Álvarez-Sala Walther, Luis; Marra, Alberto M.; del Toro-Cervera, Jorge.

In: Annals of Medicine, 01.01.2018.

Research output: Contribution to journalArticle

Peñaloza-Martínez, E, Demelo-Rodríguez, P, Proietti, M, Soria Fernández-Llamazares, G, Llamazares-Mendo, C, Álvarez-Sala Walther, L, Marra, AM & del Toro-Cervera, J 2018, 'Update on extended treatment for venous thromboembolism', Annals of Medicine. https://doi.org/10.1080/07853890.2018.1538564
Peñaloza-Martínez E, Demelo-Rodríguez P, Proietti M, Soria Fernández-Llamazares G, Llamazares-Mendo C, Álvarez-Sala Walther L et al. Update on extended treatment for venous thromboembolism. Annals of Medicine. 2018 Jan 1. https://doi.org/10.1080/07853890.2018.1538564
Peñaloza-Martínez, Eduardo ; Demelo-Rodríguez, Pablo ; Proietti, Marco ; Soria Fernández-Llamazares, Guillermo ; Llamazares-Mendo, Cristina ; Álvarez-Sala Walther, Luis ; Marra, Alberto M. ; del Toro-Cervera, Jorge. / Update on extended treatment for venous thromboembolism. In: Annals of Medicine. 2018.
@article{31d6acf2c39143e9b9b1b8fbe0b19acd,
title = "Update on extended treatment for venous thromboembolism",
abstract = "The importance of assessing the probability of venous thromboembolism recurrence, a condition that includes deep vein thrombosis and pulmonary embolism, lies in the fact that it is the most important factor in deciding the duration of anticoagulant treatment. Risk of recurrence depends mostly on the presence of a risk factor for developing venous thromboembolism, with patients with unprovoked events being at the higher risk of recurrence. The risk of recurrence needs to be balanced with the risk of bleeding and the potential severity of these thrombotic and hemorrhagic events. In patients with an unprovoked venous thromboembolism who complete treatment for the acute (first 10 days) and post-acute phase of the disease (from day 10 to 3–6 months), the decision has to be made regarding prolonged antithrombotic therapy to prevent recurrences. The main goal of extended treatment is preventing recurrences with a safety profile in terms of bleeding risk. Many therapeutic options are now available for these patients, including antiplatelet therapy with aspirin or direct oral anticoagulants. Moreover, apixaban and rivaroxaban at prophylactic doses have demonstrated efficacy in preventing recurrences with a low risk of bleeding.Key messages Extending treatment (longer than 3–6 months) is challenging in patients with venous thromboembolism (VTE) and depend on the risk of venous thromboembolism recurrence, the bleeding risk and patient and physician preferences. Anticoagulation treatment should be stopped in patients with provoked VTE and in those with unprovoked VTE and a high bleeding risk after an initial period of 3–6 months. There are some therapeutic alternatives (including Aspirin and low dose of some NOACs) to reduce venous thromboembolism recurrence risk in patients with unprovoked VTE and a low bleeding risk for extended treatment of VTE (after an initial period of 3–6 months).",
keywords = "Anticoagulation, bleeding, venous thromboembolism",
author = "Eduardo Pe{\~n}aloza-Mart{\'i}nez and Pablo Demelo-Rodr{\'i}guez and Marco Proietti and {Soria Fern{\'a}ndez-Llamazares}, Guillermo and Cristina Llamazares-Mendo and {{\'A}lvarez-Sala Walther}, Luis and Marra, {Alberto M.} and {del Toro-Cervera}, Jorge",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/07853890.2018.1538564",
language = "English",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Update on extended treatment for venous thromboembolism

AU - Peñaloza-Martínez, Eduardo

AU - Demelo-Rodríguez, Pablo

AU - Proietti, Marco

AU - Soria Fernández-Llamazares, Guillermo

AU - Llamazares-Mendo, Cristina

AU - Álvarez-Sala Walther, Luis

AU - Marra, Alberto M.

AU - del Toro-Cervera, Jorge

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The importance of assessing the probability of venous thromboembolism recurrence, a condition that includes deep vein thrombosis and pulmonary embolism, lies in the fact that it is the most important factor in deciding the duration of anticoagulant treatment. Risk of recurrence depends mostly on the presence of a risk factor for developing venous thromboembolism, with patients with unprovoked events being at the higher risk of recurrence. The risk of recurrence needs to be balanced with the risk of bleeding and the potential severity of these thrombotic and hemorrhagic events. In patients with an unprovoked venous thromboembolism who complete treatment for the acute (first 10 days) and post-acute phase of the disease (from day 10 to 3–6 months), the decision has to be made regarding prolonged antithrombotic therapy to prevent recurrences. The main goal of extended treatment is preventing recurrences with a safety profile in terms of bleeding risk. Many therapeutic options are now available for these patients, including antiplatelet therapy with aspirin or direct oral anticoagulants. Moreover, apixaban and rivaroxaban at prophylactic doses have demonstrated efficacy in preventing recurrences with a low risk of bleeding.Key messages Extending treatment (longer than 3–6 months) is challenging in patients with venous thromboembolism (VTE) and depend on the risk of venous thromboembolism recurrence, the bleeding risk and patient and physician preferences. Anticoagulation treatment should be stopped in patients with provoked VTE and in those with unprovoked VTE and a high bleeding risk after an initial period of 3–6 months. There are some therapeutic alternatives (including Aspirin and low dose of some NOACs) to reduce venous thromboembolism recurrence risk in patients with unprovoked VTE and a low bleeding risk for extended treatment of VTE (after an initial period of 3–6 months).

AB - The importance of assessing the probability of venous thromboembolism recurrence, a condition that includes deep vein thrombosis and pulmonary embolism, lies in the fact that it is the most important factor in deciding the duration of anticoagulant treatment. Risk of recurrence depends mostly on the presence of a risk factor for developing venous thromboembolism, with patients with unprovoked events being at the higher risk of recurrence. The risk of recurrence needs to be balanced with the risk of bleeding and the potential severity of these thrombotic and hemorrhagic events. In patients with an unprovoked venous thromboembolism who complete treatment for the acute (first 10 days) and post-acute phase of the disease (from day 10 to 3–6 months), the decision has to be made regarding prolonged antithrombotic therapy to prevent recurrences. The main goal of extended treatment is preventing recurrences with a safety profile in terms of bleeding risk. Many therapeutic options are now available for these patients, including antiplatelet therapy with aspirin or direct oral anticoagulants. Moreover, apixaban and rivaroxaban at prophylactic doses have demonstrated efficacy in preventing recurrences with a low risk of bleeding.Key messages Extending treatment (longer than 3–6 months) is challenging in patients with venous thromboembolism (VTE) and depend on the risk of venous thromboembolism recurrence, the bleeding risk and patient and physician preferences. Anticoagulation treatment should be stopped in patients with provoked VTE and in those with unprovoked VTE and a high bleeding risk after an initial period of 3–6 months. There are some therapeutic alternatives (including Aspirin and low dose of some NOACs) to reduce venous thromboembolism recurrence risk in patients with unprovoked VTE and a low bleeding risk for extended treatment of VTE (after an initial period of 3–6 months).

KW - Anticoagulation

KW - bleeding

KW - venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85059334604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059334604&partnerID=8YFLogxK

U2 - 10.1080/07853890.2018.1538564

DO - 10.1080/07853890.2018.1538564

M3 - Article

AN - SCOPUS:85059334604

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

ER -